Ocriplasmin
- Generic Name
- Ocriplasmin
- Brand Names
- Jetrea
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1048016-09-6
- Unique Ingredient Identifier
- 7V6HE3DM5A
- Background
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
- Indication
Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
- Associated Conditions
- Symptomatic Vitreomacular Adhesion (VMA)
- Associated Therapies
- -
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
- Conditions
- Interventions
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 628
- Registration Number
- NCT02035748
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
- Conditions
- Interventions
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 251
- Registration Number
- NCT01889251
- Locations
- 🇯🇵
Contact Alcon for Trial Locations, Tokyo, Japan
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
- Conditions
- Interventions
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 220
- Registration Number
- NCT01429441
- Locations
- 🇺🇸
Texas Retina Associates, Dallas, Texas, United States
🇺🇸Retina Associates of Cleveland, Cleveland, Ohio, United States
🇺🇸Vitroretinal Consultants, Houston, Texas, United States
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 24
- Registration Number
- NCT01287988
- Locations
- 🇧🇪
Universitaire Ziekenhuizen K.U. Leuven, Leuven, Belgium
🇺🇸Retinal Consultants of Houston, Houston, Texas, United States
Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2018-07-31
- Target Recruit Count
- 2
- Registration Number
- NCT01194674
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 38
- Registration Number
- NCT01159665
- Locations
- 🇧🇪
University Hospital Leuven, Leuven, Belgium
Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 17
- Registration Number
- NCT01055535
- Locations
- 🇧🇪
University Hospital Leuven, Leuven, Belgium
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 30
- Registration Number
- NCT00996684
- Locations
- 🇺🇸
Jules Stein Eye Institute/UCLA, Los Angeles, California, United States
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 24
- Registration Number
- NCT00986362
- Locations
- 🇺🇸
Associated Retina Consultants, Royal Oak,, Michigan, United States
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
- Conditions
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 100
- Registration Number
- NCT00913744
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Retinal Consultants of Houston,, Houston,, Texas, United States
🇬🇧Moorfields Eye Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.